Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

AIMS: This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.

MATERIALS AND

METHODS

Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined. Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.

RESULTS

Overall baseline means were cDI, 0.3 pmol*m-2*L*min-2*kg-1; M value, 5.8 mg*kg-1*min-1; ISR, 116.8 pmol*min-1*m-2. The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%). Macupatide alone significantly increased the M value and, to a lesser yet significant extent, ISR. Combination therapy was numerically greater than both monotherapies in augmenting all indices. The most frequent adverse events were injection site reactions and diarrhoea. Study discontinuations due to treatment-emergent adverse events were uncommon. There were no deaths during the study.

CONCLUSION

These findings demonstrate that chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity, and that combining GIP and GLP-1 receptor agonism can augment both insulin secretion and insulin sensitivity compared to GLP-1 therapy alone.